TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02744989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuroconn or Neuroelectric tDCS stimulator
Description: Stimulation parameters were chosen in conformity with those for the treatment of schizophrenic symptoms (Brunelin et al, 2012), adapted according to the latest data from the literature and the tDCS operating stimulator. The experimental tDCS group will receive the ACTIVE stimulation with the following parameters: oscillatory Direct Current with high frequency random noise stimulation (hf-tRNS - 100 to 500 Hz), Intensity = 2 mA, offset = + 1 mA, seance duration = 20 minutes ramp up/ramp down 30 seconds. Total number of sessions = 10 (sessions twice daily for 5 days separated by at least 2 hours for 5 consecutive weekdays).
Study: NCT03280381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nifty feeding cup
Description: The 40 mL Nifty Feeding Cup features an extended reservoir off the lip of the cup that holds a small bolus of milk, ensuring efficient delivery of milk, is made of a durable, soft, silicone material that protects the infant's mouth from injury, has embossed measurements help with tracking volume and intake of milk, is ergonomically designed for frequent use and to enhance finger and wrist control of milk flow and is made from a quick-drying, ultraviolet radiation-resistant, durable, affordable silicone that can be boiled for sterilization. Mothers can directly express into the cup, reducing possible cross-contamination from other containers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Generic medicine cup
Description: The generic cup that will be used in this study is a small medicine cup 30 ml in size.Small medicine cups are manufactured by a variety of manufacturers and are commonly used in health facilities to feed breastmilk to infants who are having breastfeeding difficulties. The cups are generally translucent, calibrated with a variety of measurements including 2.5-30 mL.
Study: NCT00491400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: 140 mg/day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: 140 mg/day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 20 mg/day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 20 mg/day for 8 weeks
Study: NCT01850342

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periurethral injection of fat micrograft enriched with ADRC
Description: Subjects will undergo liposuction under local anesthesia. One part of lipoaspirate will be processed to isolate and concentrate ADRCs. Another part of lipoaspirate will be washed and homogenized to prepare fat tissue micrograft. After that fat tissue micrograft will be mixed with ADRC. Autologous fat micrograft enriched with ADRC will be injected at the bulbomembranous region of urethra circle-wise under endoscopic vision.
Study: NCT02078518

Intervention type: OTHER
Intervention: Questionnaires
Study: NCT02177292

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: A high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
Study: NCT00701259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 15 mg once per day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 30 mg once per day for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00201045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physician/Pharmacist Collaborative Teams
Description: The patient's physician collaborates with a clinical pharmacist to improve management of hypertension
Study: NCT01672684

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: support group therapy
Description: Complete at-home group video calling support sessions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive an educational workbook journal
Study: NCT01698541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tested generic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tested generic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Original formulation used as comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Original formulation used as comparator
Study: NCT01503450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine OD Tablets 5 mg
Description: Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine OD Tablets 5 mg
Description: Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
Study: NCT01378884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Patient to receive treatment with Domperidone
Study: NCT03195998

Intervention type: DIAGNOSTIC_TEST
Intervention: TcB Measurement
Description: TcB measurements will be obtained within approximately 30 minutes of the TSB being drawn before initiation of phototherapy, approximately 24 hours after the initiation of phototherapy and approximately 24 hours after completion of phototherapy. The TcB measurement will involve lightly pushing three times at each site which will yield an average transcutaneous bilirubin value. This will be calculated for the interscapular, buttock and sternal automatically by the bilirubinometer. While on phototherapy a measurement of the diapered, non-exposed buttock area will be obtained at approximately 24 hours to coincide with the standard of care serum bilirubin measurement.

Intervention type: DIAGNOSTIC_TEST
Intervention: TcB Measurement
Description: TcB measurements will be obtained within approximately 30 minutes of the TSB being drawn before initiation of phototherapy, approximately 24 hours after the initiation of phototherapy and approximately 24 hours after completion of phototherapy. The TcB measurement will involve lightly pushing three times at each site which will yield an average transcutaneous bilirubin value. This will be calculated for the interscapular, buttock and sternal automatically by the bilirubinometer. While on phototherapy a measurement of the diapered, non-exposed buttock area will be obtained at approximately 24 hours to coincide with the standard of care serum bilirubin measurement.
Study: NCT03280381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Generic medicine cup
Description: The generic cup that will be used in this study is a small medicine cup 30 ml in size.Small medicine cups are manufactured by a variety of manufacturers and are commonly used in health facilities to feed breastmilk to infants who are having breastfeeding difficulties. The cups are generally translucent, calibrated with a variety of measurements including 2.5-30 mL.
Study: NCT02039401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VM202
Study: NCT03353285

Intervention type: PROCEDURE
Intervention: intracytoplasmic sperm injection (ICSI)
Description: All eggs will be fertilized by ICSI

Intervention type: PROCEDURE
Intervention: intracytoplasmic sperm injection (ICSI)
Description: All eggs will be fertilized by ICSI

Intervention type: PROCEDURE
Intervention: intracytoplasmic sperm injection (ICSI)
Description: All eggs will be fertilized by ICSI
Study: NCT05013398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Together Webinar Programme
Description: The TTP-Webinar consists of six hour-long sessions. Each session focuses on psychoeducation and self-management strategies for supporting veteran mental health difficulties as well as self-management tools to enhance partners' own wellbeing.~The TTP-Webinar treatment protocol incorporates a range of techniques used in Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), Compassion Focused Therapy (CFT), and Acceptance and Commitment Therapy (ACT).
Study: NCT04150016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a nonsurgical procedure that improves blood flow to your heart.PCI requires cardiac catheterization, which is the insertion of a catheter tube and injection of contrast dye, usually iodine-based, into your coronary arteries. Doctors use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI may be used to relieve symptoms of coronary heart disease or to reduce heart damage during or after a heart attack.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a nonsurgical procedure that improves blood flow to your heart.PCI requires cardiac catheterization, which is the insertion of a catheter tube and injection of contrast dye, usually iodine-based, into your coronary arteries. Doctors use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI may be used to relieve symptoms of coronary heart disease or to reduce heart damage during or after a heart attack.
Study: NCT02744989

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: The control group will receive the SHAM stimulation (placebo) following the same regimen (i.e., twice daily sessions separated by at least 2 hours for 5 consecutive weekdays). Sham stimulation consists of a 20 minutes session including 40 seconds of active stimulation (same parameters as in the ACTIVE arm) at the beginning of the sessions, whatever the stimulator
Study: NCT00407732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychosocial intervention
Description: motivational enhancing case management intervention
Study: NCT03439670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vamorolone
Description: Oral administration of 6.0 mg/kg/day for 20 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vamorolone
Description: Oral administration of 6.0 mg/kg/day for 20 weeks.
Study: NCT03192943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Specified dose on specified days
Study: NCT02536846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: All subjects will take a single 2.5 mg dose of olanzapine (Zyprexa Zydis) followed by a 5 mg dose for 14 days. (2.5 mg/d for 1 day, 5 mg/d for 14 days).
Study: NCT04194645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 tablet
Description: BI 474121 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 tablet
Description: BI 474121 tablet
Study: NCT05141656

Intervention type: OTHER
Intervention: No intervention will be considered in this study.
Description: No intervention will be considered in this study.
Study: NCT03192943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day
Study: NCT02283047

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DIET
Description: Lifestyle intervention through hypocaloric diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIET & MODERATE CONTINUOUS TRAINING
Description: Lifestyle intervention through hypocaloric diet and exercise at moderate intensity (60-80%peakHR) continuous mode, and high volume (45 min).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIET & HIGH VOLUME HIIT
Description: Lifestyle intervention through hypocaloric diet and exercise at high intensity (80-95%peakHR) interval mode, and high volume (45 min).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIET & LOW VOLUME HIIT
Description: Lifestyle intervention through diet and exercise at high intensity (80-95%peakHR) interval mode, and low volume (20 min).
Study: NCT01355445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine, Irinotecan
Description: * D1 and D8: Vincristine 1.5 mg/m² (max 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~* D1 to D5: Irinotecan 50 mg/m²/d, IV~  1. cycle / 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine, Irinotecan, Temozolomide
Description: * D1 to D5: Temozolomide 125 mg/m²/d, PO (the dose will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience \> grade 3 toxicity of any kind)~* D1 and D8: Vincristine 1.5 mg/m² (maximum 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)~* D1 to D5: Irinotecan 50 mg/m²/d, IV~  1. cycle / 21 days
Study: NCT01487460

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAP311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAP311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAP311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAP311
Study: NCT02753998

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Additional angioplasty with paclitaxel-coated balloon
Description: Additional angioplasty with paclitaxel-coated balloon after conventional angioplasty

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Additional angioplasty with placebo balloon
Description: Additional angioplasty with placebo balloon after conventional angioplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional angioplasty

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional angioplasty
Study: NCT00729794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone
Description: Combination Treatment~Administration of vasopressin, epinephrine, and methylprednisolone during CPR, and of stress dose hydrocortisone after CPR

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard CPR Protocol with Epinephrine and two Placebos
Description: Patients receive advanced life support according to the Guidelines for Resuscitation 2005
Study: NCT03315377

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lunate-Capitate Fusion (LCF)
Description: Operation with lunate-capitate-fusion (LCF)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four Corner Fusion (4CF)
Description: Operation with four-corner-fusion (4CF)
Study: NCT04732104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine topical
Description: intranasal spray anesthesia will be administered for achieving pulpal local anesthesia of maxillary anterior and premolar teeth. Xylometazoline OTC decongestant will be used to prolong the duration of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: injectable local anesthesia will be administered to achieve pulpal local anesthesia of maxillary anterior and premolar teeth
Study: NCT02519868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical block
Description: Nerve stimulator switched on at an intensity of 5 mA for 15 minutes, with the needle tip positioned close to the carotid bifurcation with the aid of the echography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chemical block
Description: Injection of lidocaine 1%, 15 mLs, with the needle tip positioned close to the carotid bifurcation, with the aid of the echography
Study: NCT02915185

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: strength training intervention
Description: The strength training program will last 4 weeks (3 times/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb, which are the wrist extensors and the elbow and shoulder flexors. In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Participants' maximal grip force will be determined and used to dose the training of the hand muscles and its progression. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: An anodal montage over the ipsilesional hemisphere will be used where the anode will be placed over the ipsilesional M1 area whereas the cathode will be placed on the contralateral supra-orbital region.For the tDCS real group, a direct current will be generated by a tDCS stimulator and gradually increased in a ramp-like fashion over the first 8 seconds until a maximum intensity of 2 mA is achieved. The tDCS will be applied for 20 minutes during each training session for a total of 12 sessions. For the group receiving sham tDCS, the protocol will be similar to the tDCS real group although the stimulation will be applied for the first 30 seconds only; a duration long enough to induce similar perceived sensation as real tDCS (tingling), to keep participants' blind to the tDCS type.
Study: NCT01164553

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Inactivated Influenza Vaccine
Description: Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh with a 25 gauge 1 inch needle. Naive cohort (enrolled over two influenza seasons (2010-11 and 2011-12)) will receive vaccine in two IM doses 28-42 days apart, Fully Primed cohort (enrolled in one influenza season (2010-11)) will receive vaccine in one IM dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Influenza Vaccine
Description: Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh with a 25 gauge 1 inch needle. Naive cohort (enrolled over two influenza seasons (2010-11 and 2011-12)) will receive vaccine in two IM doses 28-42 days apart, Fully Primed cohort (enrolled in one influenza season (2010-11)) will receive vaccine in one IM dose.
Study: NCT01670565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept ®) for the treatment of early diffuse cutaneous systemic sclerosis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Patients received background MMF therapy, some who were naive to MMF were titrated up to 1,000 mg twice daily and others had been receiving MMF at \<2,000 mg/day for \<3 months. MMF was chosen so that background therapy would be uniform and not a further source of variability in the small study.
Study: NCT01947920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl, 50 mg
Description: 50-mg overencapsulated tablet for oral administration
Study: NCT04194645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 tablet
Description: BI 474121 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 tablet
Description: BI 474121 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 tablet
Description: BI 474121 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 tablet
Description: BI 474121 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 tablet
Description: BI 474121 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 474121 tablet
Description: BI 474121 tablet
Study: NCT02915211

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Keyo
Description: Keyo is a Food for Special Medical Purposes (FSMP) and is intended for use in the KD. It has a fat to protein and carbohydrate ratio of 3 to 1. This makes it appropriate for inclusion in all versions of the KD - classical, MCT, MAD and LGI. Keyo has been designed as a nutritionally complete, ready to use, pleasant tasting and versatile medical food for use in a KD.
Study: NCT02291406

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal hysterectomy
Description: Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
Study: NCT02291406

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot assisted laparoscopic hysterectomy
Description: Robotic assisted total laparoscopic hysterectomy.
Study: NCT01670565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Patients received background MMF therapy, some who were naive to MMF were titrated up to 1,000 mg twice daily and others had been receiving MMF at \<2,000 mg/day for \<3 months. MMF was chosen so that background therapy would be uniform and not a further source of variability in the small study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion
Description: Infusion of normal saline
Study: NCT03873506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transplantation of hUC-MSCs
Description: Human umbilical cord-derived mesenchymal stem cells had given to preterm infants through intravenous infusion.
Study: NCT03476161

Intervention type: DEVICE
Group type: OTHER
Intervention: 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive. 4069-6103 / 4069-6114 / 4069-6203 / 4069-6214
Description: One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.

Intervention type: DEVICE
Group type: OTHER
Intervention: 3M Unitek Victory Series™ Superior Fit Buccal Tube with APC™ Flash-Free Adhesive. 4069-6103 / 4069-6114 / 4069-6203 / 4069-6214
Description: One type of first permanent molar buccal tube used for fixed orthodontic treatment. One types of adhesive, with same buccal tube base.
Study: NCT05569343

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any intervention

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any intervention